Related Experiment Video
Updated: Apr 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?
Colleen M Hanley1, Peter R Kowey1
11 Clinical Cardiac Electrophysiology Fellow, Lankenau Medical Center, Wynnewood, USA ; 2 System Chief, Division of Cardiovascular Disease, Main Line Health Hospitals, William Wikoff Smith, Chair in Cardiovascular Research, Lankenau Institute for Medical Research, Professor of Medicine and Clinical Pharmacology, Jefferson Medical College, Philadelphia, PA, USA.
Abstract:
Atrial fibrillation (AF) is associated with significant morbidity and mortality related to stroke due to thromboembolism. Several novel oral anticoagulants (NOACs) have been developed that dose-dependently inhibit thrombin or activated factor X (factor Xa). These new agents offer potential advantages over vitamin K antagonists, however, several limitations exist. We will review the four large randomized trials comparing the efficacy and safety of new oral anticoagulants with warfarin for stroke prevention in patients with AF as well as assess "real world" data and discuss the limitations of the new agents.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Cardiovascular Drugs: Classification based on Therapeutic Indications

